HGH vs Peptides: What Each One Actually Delivers

Ask about HGH vs peptides at most clinics and you will get an answer about which one works better. That is the wrong frame, and it produces a lot of confused patients. In the United States the question is settled first by statute, and only afterward by clinical judgment.

Patients ask us a version of this constantly — some phrasing of why sermorelin or CJC-1295 instead of actual growth hormone? It is a fair question with a specific answer, and the answer is worth knowing before you shop.

The Legal Situation, First

Human growth hormone occupies an unusual place in US law. It is not simply a prescription drug that a physician may use off-label at their discretion, the way most drugs are.

Under 21 U.S.C. § 333(e), it is a federal offense to knowingly distribute or possess with intent to distribute human growth hormone for any use in humans other than the treatment of a disease or other recognized medical condition where that use has been authorized by the Secretary of Health and Human Services and is pursuant to a physician’s order (1). The FDA interprets “distribution” to include the act of writing the prescription.

For adults, the authorized indications amount to three:

• Growth hormone deficiency, diagnosed properly
• HIV-associated wasting
• Short bowel syndrome

Age-related decline in growth hormone is not on the list, because normal aging is not a disease or recognized medical condition under that statute. This is why a clinic advertising real injectable HGH for anti-aging is either describing something other than what it is selling, or operating outside the law. Our article on the legal and FDA status of peptide therapy covers the adjacent regulatory framework for compounded peptides.

That constraint is the entire reason the peptide category exists in longevity medicine.

What Growth Hormone Deficiency Actually Is

Because GHD is the one adult indication most people might plausibly have, it is worth being precise about it. It is a real, diagnosable condition, and it is not the same thing as having a growth hormone level lower than you would like.

Adult GHD usually results from pituitary or hypothalamic disease, pituitary surgery, cranial radiation, or traumatic brain injury. The Endocrine Society’s clinical practice guideline is explicit that diagnosis generally requires provocative testing — a stimulation test — rather than a single hormone measurement (2).

IGF-1 is the screening marker, but it is an imperfect one. A low IGF-1 in the absence of confounders such as poorly controlled diabetes, liver disease, or oral estrogen is strong evidence of significant GHD. A normal IGF-1 does not exclude it, which is why provocative testing becomes mandatory when the clinical picture suggests deficiency (3, 4).

The practical upshot: if you have a genuine pituitary problem, you need an endocrinology workup and you may be a candidate for growth hormone itself. If your IGF-1 is simply toward the low end of the range for your age and you feel less recovered than you did at 30, you do not have GHD — and the honest conversation is about secretagogues, training, and sleep.

HGH vs Peptides: The Core Difference

Both routes end at the same hormone. They arrive by different paths, and the path determines nearly everything that follows.

Injected HGH delivers growth hormone directly into circulation. It does not require a working pituitary, it produces a sustained rather than pulsatile elevation, and it bypasses the feedback loop that normally limits growth hormone output. That last point is what makes it powerful and also what makes supraphysiologic dosing possible.

Growth hormone peptides act one step upstream, on the pituitary. They fall into two families:

• GHRH analogues — sermorelin, tesamorelin, CJC-1295 — mimic growth-hormone-releasing hormone and prompt the pituitary to release a pulse of its own growth hormone.
• Ghrelin-receptor agonists (GHRPs) — ipamorelin, hexarelin — act through a separate receptor to amplify that release, which is why they are frequently paired with a GHRH analogue rather than used alone.

Because release still originates in your pituitary, somatostatin feedback still applies. The body retains a ceiling. That is the defining trade-off of the category: less capacity to drive levels high, and correspondingly less capacity to drive them to a harmful place.

What the Evidence Supports for Each Peptide

This is where the category deserves more candor than it usually gets. The peptides are not interchangeable, and their evidence bases are very different in strength.

Tesamorelin has the strongest data by a wide margin, because it is FDA-approved. Approval came in 2010 for inducing and maintaining a reduction of excess visceral abdominal fat in people with HIV-associated lipodystrophy, based on two trials enrolling 816 adults (5). A newer formulation was approved in 2025. The approval is population-specific, so use outside HIV-associated lipodystrophy is off-label — but the visceral-fat effect was demonstrated in registrational trials, not inferred. Our articles on tesamorelin benefits and sermorelin vs tesamorelin go further into where it fits.

Sermorelin is a truncated GHRH analogue that was previously FDA-approved as Geref for growth hormone deficiency in children. It was withdrawn from the market for commercial reasons rather than safety findings, and it is now supplied by compounding pharmacies. It has the longest clinical track record in this category and a well-characterized mechanism; what it lacks is modern registrational trial data for body composition in healthy aging adults. See sermorelin before and after for what is realistic to expect.

CJC-1295 and ipamorelin are widely used, frequently together, and have the thinnest human outcome data of the group. The mechanistic rationale is sound and the pairing is logical — a GHRH analogue plus a GHRP produce a larger pulse than either alone. But mechanistic coherence is not the same as demonstrated outcomes, and it is worth being honest that most of what is claimed for this combination rests on short-term hormone measurements and clinical experience rather than long trials. Our comparison of sermorelin vs CJC-1295 lays out the differences.

If you want the wider category overview first, what is peptide therapy is the better starting point.

What Results Look Like, and on What Timeline

Expectations are where this category goes wrong most often, so here is the realistic version.

Weeks 1–4. The changes most commonly reported first are sleep quality and subjective recovery. Growth hormone release is tightly coupled to deep sleep, and patients frequently notice this before anything else. There is nothing measurable to check this early other than tolerance.

Weeks 8–12. This is the first meaningful lab checkpoint. IGF-1 is the marker, and the question is whether it moved into a reasonable range for your age — not whether it went as high as possible. If IGF-1 has not budged, the protocol is wrong, the pituitary response is limited, or adherence is the issue, and that is worth knowing at three months rather than at twelve.

Months 3–6. Body composition, if it changes, changes on this timescale, and it should be assessed with a scan rather than a mirror. Realistic expectations are modest shifts in lean mass and visceral fat alongside training and adequate protein — not a transformation, and not a substitute for either.

Ongoing. Periodic IGF-1, fasting glucose and HbA1c, because growth hormone signalling affects insulin sensitivity and that is the metabolic variable most worth watching.

What should not be promised: dramatic fat loss, a return to a 25-year-old’s recovery, or a specific pound or inch figure. Anyone quoting those is describing marketing rather than a protocol.

What an IGF-1 Target Actually Means

One clarification, because it drives a lot of poor prescribing. The goal of a secretagogue protocol is not the highest IGF-1 you can produce. IGF-1 has a reference range that falls with age, and the reasonable objective is generally the upper part of the range appropriate for your age rather than the range of a 25-year-old.

There are two reasons for that restraint. Higher is not established as better for outcomes in healthy aging adults, and IGF-1 signalling sits in the middle of a genuinely unresolved question in longevity biology — lower IGF-1 is associated with longer lifespan in several model organisms, while higher IGF-1 supports the lean mass and recovery people are seeking. Pushing a 55-year-old’s IGF-1 to the top of a 25-year-old’s range is a choice made without evidence that it helps and with some reason to think it may not.

This is a reasonable thing to ask a prescriber about directly: what number are we aiming for, and why that one.

Safety, Honestly

Growth hormone excess has a well-documented symptom set, and it is the reason the feedback loop matters.

Supraphysiologic growth hormone is associated with fluid retention and edema, joint pain, carpal tunnel symptoms, and worsening insulin resistance. Because secretagogues work through the pituitary and remain subject to somatostatin feedback, they are less able to produce that picture — but “less able” is not “unable,” and these effects have been reported with aggressive secretagogue protocols.

The common and manageable effects are injection-site reactions, transient flushing, and occasional water retention early on. The situations where this category should be avoided include active malignancy, certain pituitary lesions, and proliferative retinopathy, and there are others that depend on individual history. Growth hormone and its secretagogues are also prohibited in competitive sport, which matters if you are tested.

This is the part that does not work as a mail-order product. The reason to run growth hormone peptides under supervision is not liability theatre — it is that IGF-1 and glucose need checking, dose needs adjusting to a result, and the decision to stop is as clinical as the decision to start.

What About the “HGH” Sold Online?

Given the legal picture above, it is worth being direct about what is actually in the vials sold on the internet as growth hormone, because patients arrive having bought them.

Broadly there are four possibilities, and none of them is good. The product may be counterfeit — containing no growth hormone, or a fraction of the labelled amount. It may be genuine somatropin diverted from a legitimate supply chain, in which case the person selling it is committing a federal offense and the person buying it has no assurance of storage or handling. It may be a secretagogue relabelled as growth hormone, which is a different drug at a different price. Or it may be a research-grade preparation manufactured without pharmaceutical quality control, where sterility and purity are unverified.

The practical tells are not subtle. Growth hormone requires cold-chain handling, so anything shipped without refrigeration is suspect on arrival. Price is the other signal: legitimate somatropin is expensive, and a price that seems too good generally is. Independent testing of grey-market peptide and hormone products has repeatedly found mislabelled and substandard material, which is the same problem the compounded peptide market has, one tier worse.

There is also exposure that patients rarely consider. Because § 333(e) restricts distribution and possession with intent to distribute, the legal risk is not confined to the seller. This is not a hypothetical concern for a product being shipped across state lines.

If you have already bought something and want to know what it did to you, the useful step is measuring IGF-1 rather than guessing — and stopping until you know.

The Questions Worth Asking a Clinic

If you are evaluating a growth hormone program, these are the questions that separate a clinical protocol from a subscription. They are also the questions we would want asked of us.

• Is this actual growth hormone or a secretagogue? The answer should be immediate and unambiguous. If a clinic is vague here, that is the answer.
• What is my IGF-1 before we start? Beginning without a baseline means there is nothing to measure against later.
• What will you recheck, and when? IGF-1 at 8 to 12 weeks is the minimum. Fasting glucose and HbA1c belong in the same draw.
• What happens if IGF-1 does not move? A protocol with no answer to this is not a protocol. The possible answers — adjust the dose, reconsider the agent, investigate the pituitary, stop — are all reasonable; having none is not.
• Who is supervising, and can I reach them? Growth hormone signalling affects glucose metabolism. Someone should be reading the labs.
• Which pharmacy, and is it licensed in my state? Compounded peptides come from 503A or 503B facilities, and the difference in oversight is meaningful.
• What is the exit plan? Reasonable answers exist for how long to continue and what stopping looks like. “Indefinitely” is a business model rather than a plan.
• Am I being screened for the things that rule this out? Active malignancy and certain pituitary findings should be asked about before a prescription, not after.

A clinic that welcomes these questions is the kind you want. One that treats them as obstacles has told you what you needed to know.

How We Approach It at Rewind

Our growth hormone peptide therapy program uses secretagogues rather than synthetic growth hormone, and the reasoning is the whole of this article: for age-related decline, that is what the law permits and what the physiology argues for.

In practice that means a baseline panel including IGF-1 before anything is prescribed, a referral for a proper endocrine workup when the picture suggests genuine pituitary disease rather than age-related change, selection among sermorelin, tesamorelin, and combination protocols based on your goal and labs, and a recheck at 8 to 12 weeks that actually changes the plan.

If you have been quoted real HGH for anti-aging somewhere, that is the clearest signal available about the clinic quoting it. And if you want to know whether your own growth hormone axis is where it should be for your age, that starts with a panel and a conversation.

This article is for general education and is not medical advice. Growth hormone and peptide therapy require evaluation of your individual history, laboratory testing, and ongoing clinical supervision. Discuss any treatment with a qualified clinician.

Sources

1. 21 U.S.C. § 333 — Penalties; distribution of human growth hormone. Cornell Legal Information Institute. law.cornell.edu/uscode/text/21/333
2. Molitch ME, et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. academic.oup.com/jcem/article/96/6/1587/2833853
3. Diagnosing growth hormone deficiency in adults. PMC. ncbi.nlm.nih.gov/pmc/articles/PMC3412109/
4. IGF-I measurements in the diagnosis of adult growth hormone deficiency. PubMed. pubmed.ncbi.nlm.nih.gov/17429593/
5. FDA approves tesamorelin for HIV-related lipodystrophy. Am J Health Syst Pharm. academic.oup.com/ajhp/article/67/24/2082/5129928